Rapamycin stands as the most robust and reproducible pharmacological intervention for extending lifespan across the evolutionary spectrum, from yeast to mammals. While animal data is overwhelming, leading longevity researchers are currently locked in a complex debate regarding the safety, dosing, and potential functional trade-offs of using this drug in healthy humans [1]. This expert-led exploration…

Bryan Johnson, the tech entrepreneur spending $2 million a year to reverse his biological age, recently shocked the longevity community by announcing a Bryan Johnson Rapamycin reset. For a man who built his entire life around the Blueprint protocol, stopping a foundational longevity drug highlights the volatile nature of extreme biohacking. This decision followed a…

Your body’s metabolism is like a high-performance engine. Over time, it builds up cellular waste or "junk". For decades, researchers sought a biological switch to trigger autophagy. This is a vital self-cleaning mode for cells. Rapamycin is the most promising switch discovered so far. It was originally found in the soil of Easter Island. The…

Cardiovascular disease remains the leading cause of mortality worldwide, with aging serving as the primary risk factor. As we age, the heart and blood vessels undergo progressive changes—including increased arterial stiffness, impaired relaxation (diastolic dysfunction), and a decline in endothelial health—often long before clinical symptoms appear. Rapamycin, an FDA-approved compound originally used in organ transplantation,…

Recent clinical research highlights a distinction in rapamycin dosing. Chronic high doses can blunt acute protein synthesis. However, intermittent dosing for longevity does not necessarily prevent muscle growth. This is especially true when paired with consistent resistance training. Individuals should understand the nuance between acute inhibition and long-term adaptation. This knowledge allows them to balance…

The landscape of chronic illness treatment is shifting as researchers move beyond mere symptom management toward addressing the biological roots of exhaustion. As we move through 2026, a clear trend has emerged: rapamycin, once known primarily as a transplant drug and longevity "miracle," is being repurposed as a precision tool for patients battling Long COVID…

Rapamycin is the strongest drug candidate in longevity research so far, but it is not yet a proven “true anti-aging drug” in humans. The evidence is compelling in animals and promising in early human studies, yet we still lack the kind of large, long-term trials needed to say it reliably slows human aging. Rapamycin sits…

People are tracking the latest breakthroughs in clinical longevity, already know that rapamycin has shifted from a niche immunosuppressant to the most heavily debated molecule in geroscience. But exactly why would a doctor prescribe rapamycin today? For decades, the FDA has approved rapamycin (known generically as sirolimus) specifically to prevent organ transplant rejection and treat…

Rapamycin shows promise in slowing or partially reversing epigenetic clocks in preclinical models like human skin cells and mice, however human clinical evidence remains limited and mixed. Experts like Matt Kaeberlein highlight ongoing dog trials as key tests for translation, while users report variable biomarker shifts alongside side effects. This post dives into mechanisms, data,…

Rapamycin inhibits mTORC1 rapidly but can disrupt mTORC2 with prolonged or high exposure, potentially leading to insulin resistance, immune suppression, and endothelial damage—serious risks for longevity seekers. Intermittent low dosing minimizes mTORC2 impact while preserving benefits like autophagy induction. Experts like Peter Attia and Matt Kaeberlein advocate pulsed protocols to balance these effects. How Does…